Dr. Wong on Anti-Amyloid Fibril Treatments in AL Amyloidosis

Sandy Wong, MD
Published: Monday, Feb 05, 2018



Sandy Wong, MD, assistant professor, University of California, San Francisco School of Medicine, discusses anti-amyloid fibril treatments, a class of agents that have yet to receive FDA approval in the treatment of patients with immunoglobulin light chain amyloidosis (AL amyloidosis).

The NEOD001 agent has received a lot of attention over the past couple years. It is an anti-amyloid fibril monoclonal antibody that works against the amyloid fibrils to clean up the amyloid deposits in the body, allowing for organ recovery.

Early-phase studies reveal that it was well-tolerated in a first-in-human study of 27 patients with AL amyloidosis. The phase I trial, published in the Journal of Clinical Oncology, detailed a promising safety profile. Preliminary data also showed cardiac, renal, and neurologic responses.

The other anti-amyloid fibril therapy is CAEL-101. Data presented at the 2017 ASH Annual Meeting suggested that this drug looks similar to NEOD001 with regard to efficacy and safety.
 


Sandy Wong, MD, assistant professor, University of California, San Francisco School of Medicine, discusses anti-amyloid fibril treatments, a class of agents that have yet to receive FDA approval in the treatment of patients with immunoglobulin light chain amyloidosis (AL amyloidosis).

The NEOD001 agent has received a lot of attention over the past couple years. It is an anti-amyloid fibril monoclonal antibody that works against the amyloid fibrils to clean up the amyloid deposits in the body, allowing for organ recovery.

Early-phase studies reveal that it was well-tolerated in a first-in-human study of 27 patients with AL amyloidosis. The phase I trial, published in the Journal of Clinical Oncology, detailed a promising safety profile. Preliminary data also showed cardiac, renal, and neurologic responses.

The other anti-amyloid fibril therapy is CAEL-101. Data presented at the 2017 ASH Annual Meeting suggested that this drug looks similar to NEOD001 with regard to efficacy and safety.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x